BioXcel Therapeutics Inc.
BTAI | NASDAQ
$0.18
-$0.54 (-74.96%)
Aug 28, 2026, 4:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 642K | 2.27M | 1.38M | 375K | n/a | n/a |
Cost of Revenue | 164K | 2.14M | 1.26M | 20K | n/a | n/a |
Gross Profit | 478K | 123K | 120K | 355K | n/a | n/a |
Operating Income | -50.27M | -67.25M | -171.78M | -159.65M | -106.94M | -82.3M |
Interest Income | 1.07M | 2.6M | 5.65M | 2.53M | 4K | 155K |
Pretax Income | -69.9M | -59.6M | -179.05M | -165.76M | -106.93M | -82.17M |
Net Income | -69.9M | -59.6M | -179.05M | -165.76M | -106.93M | -82.17M |
Selling & General & Admin | 20.49M | 34.49M | 83.41M | 68.76M | 54.23M | 24.65M |
Research & Development | 30.25M | 30.44M | 84.33M | 91.24M | 52.71M | 58.54M |
Other Expenses | n/a | 2.44M | 4.16M | n/a | -1K | -888K |
Operating Expenses | 50.75M | 67.37M | 171.9M | 160M | 106.94M | 82.3M |
Interest Expense | 16.98M | 15.13M | 13.31M | 8.21M | 40K | 27K |
Selling & Marketing Expenses | 407K | 1.39M | 19.9M | 13.01M | n/a | 345K |
Cost & Expenses | 50.91M | 69.51M | 173.16M | 160.02M | 106.94M | 82.3M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 12.21M | 2.54M | 1.82M | 1.75M | 1.65M | 1.36M |
Shares Outstanding (Diluted) | 12.21M | 2.54M | 1.82M | 1.75M | 1.65M | 1.36M |
EPS (Basic) | -5.73 | -23.51 | -98.35 | -94.67 | -64.87 | -60.63 |
EPS (Diluted) | -5.73 | -23.51 | -98.35 | -94.67 | -64.87 | -60.63 |
EBITDA | -52.61M | -44.16M | -165.42M | -157.22M | -106.6M | -82.11M |
EBIT | -52.91M | -44.47M | -165.74M | -157.54M | -106.89M | -82.3M |
Depreciation & Amortization | 300K | 309K | 318K | 327K | 297K | 188K |
Add to Watchlist
Select watchlists to add or remove BTAI